CellSource CoTSE:4880 -2.15%69 Interest Coverage is 258.14 as of Apr. 2026, which is 96% below its 10-year median of 6,672.41. GuruFocus rates TSE:4880 with a GF Score™ of 69/100 and a GF Value™ of 円781.48 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 377 Biotechnology companies, CellSource Co ranks better than 54.38% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. CellSource Co's
Operating Income
for the
six
months ended in Apr. 2026 was 円126 Mil. CellSource Co's Interest Expense for the
six
months ended in Apr. 2026 was 円-0 Mil.
CellSource Co's interest coverage for the quarter that ended in Apr. 2026 was 258.14.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. CellSource Co Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for CellSource Co's Interest Coverage or its related term are showing as below:
TSE:4880'
s Interest Coverage Range Over the Past 10 Years
Min: 94.83 Med: 6672.41 Max: 142823.36
Current: 222.59
TSE:4880's Interest Coverage is ranked better than 54.38% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs TSE:4880: 222.59
CellSource Co (TSE:4880) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
CellSource Co Interest Coverage Related Terms
CellSource Co Interest Coverage Historical Data
* Premium members only.
The historical data trend for CellSource Co's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
TSE:4880 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, CellSource Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSource Co Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSource Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where CellSource Co's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellSource Co (TSE:4880) has a Interest Coverage of 258.14 as of Apr. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on CellSource Co and its competitors. This is 96% below median its historical median of 6,672.41. Over the past decade, CellSource Co's Interest Coverage has ranged from 94.83 to 142,823.36. According to the industry distribution chart, CellSource Co ranks #172 out of 377 companies in the Biotechnology industry, placing it in the top 45.6%.
Is CellSource Co's Interest Coverage too high?
CellSource Co's current Interest Coverage of 258.14 is 96% below median its 10-year median of 6,672.41. Over the past 10 years, this metric has ranged from a low of 94.83 to a high of 142,823.36. The Biotechnology industry median Interest Coverage is 106.07. CellSource Co's value of 258.14 is 143.4% above this industry median. Based on the distribution chart, CellSource Co ranks #172 out of 377 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CellSource Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CellSource Co ranks #172 out of 377 companies for Interest Coverage. This puts CellSource Co in the upper half of its industry. The industry median Interest Coverage is 106.07. CellSource Co's value of 258.14 is 143.4% above this benchmark. Historically, CellSource Co's own Interest Coverage has ranged from 94.83 to 142,823.36 over the past decade. While the company's 10-year median is 6,672.41 vs. the industry median of 106.07, CellSource Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellSource Co's current Interest Coverage of 258.14 is 143.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on CellSource Co and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellSource Co's current Interest Coverage is 258.14, which is 96% below median its own 10-year median of 6,672.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円781.48, compared to a current price of 円319.00 — trading 59.2% below its estimated fair value. The current Interest Coverage is 258.14, which is 96% below median its 10-year median of 6,672.41 and 143.4% above the Biotechnology industry median of 106.07. CellSource Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current Interest Coverage is 258.14 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSource Co (TSE:4880) Overvalued in 2026?
Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued.
The current stock price of 円319.00 is trading 59.2% below its estimated GF Value™ of 円781.48.
GuruFocus considers CellSource Co to be Significantly Undervalued.
Key valuation signals for TSE:4880:
Interest Coverage: 258.14 (96% below median its 10-year median of 6,672.41)
GF Value™: 円781.48 vs. price of 円319.00 (59.2% below fair value)
Industry Position: 143.4% above the Biotechnology median (#172 of 377)
No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
69GF Score
Get the complete analysis for TSE:4880
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4880 has been successfully added to your 
